<DOC>
	<DOC>NCT00141271</DOC>
	<brief_summary>This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.</brief_summary>
	<brief_title>A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in Diagnostic and Statistical Manual (of Mental Disorders) Fourth Edition Text Revision (DSMIVTR) (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI) Subjects with a DSMIV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (298.9). Subjects with other DSMIV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Bipolar I Disorder</keyword>
</DOC>